La cadena de opciones muestra datos clave de las opciones de acciones de BioCardia a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioCardia..

BioCardia (NASDAQ:BCDA) Bolsa, Cadena de Opciones

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

News

Management

AVNS

Avanos Medical Taps David Pacitti As Chief Executive Officer, Effective April 14

Rebecca Kujawa, president and chief executive officer (CEO), NextEra Energy Resources, LLC, will be retiring on May 22, 2025, as part of a planned leadership succession process.
Brian Bolster, currently executive vice president and chief financial officer (CFO) of NextEra Energy, will succeed Kujawa as president and CEO at NextEra Energy Resources.

NextEra Energy Names Mike Dunne As Executive Vice President, Finance And CFO

Contracts

Centene Subsidiary,  Meridian Health Plan of Illinois, To Continue Providing Medicare And Medicaid Services For Dually Eligible Members In Illinois

ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 8.77 percent decrease over losses of $(0.57) per share from the same period last year.

Earnings

PROK

ProKidney FY 2024 GAAP EPS $(0.62) Misses $(0.57) Estimate, Ended The Fourth Quarter With $358M In Cash And Cash Equivalents And Marketable Securities, Supporting Operations Into Mid-2027

Jefferies analyst Peter Abramowitz initiates coverage on BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Buy rating and announces Price Target of $78.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On BXP with Buy Rating, Announces Price Target of $78

IREN

IREN Secures Grid Access For Sweetwater 2 As Part Of 2.75GW AI-Optimized Data Center Expansion In West Texas

Jefferies analyst Peter Abramowitz initiates coverage on Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Hold rating and announces Price Target of $100.

Jefferies Initiates Coverage On Alexandria Real Estate with Hold Rating, Announces Price Target of $100

NOTE

FiscalNote Launches Presidential Actions Widget, An Advanced New Feature Within Its PolicyNote Platform

On Friday, March 14, U.S. markets closed sharply higher as investors hunted for bargains following a turbulent week marked by rising recession fears and escalating trade tensions under President Trump. A strong tech-led rebound boosted major indexes, though all three still posted weekly losses.
Persistent uncertainty, fueled by mixed inflation data, plunging consumer sentiment, and erratic policy signals, continues to rattle investor confidence and amplify economic concerns.
In economic data, University of Michigan consumer sentiment fell to 57.9 in March, the lowest since November 2022, below February&#8217;s 64.7 and expectations of 63.1.
All S&amp;P 500 sectors ended higher on Friday, led by strong gains in technology, energy, and financial stocks.
The Dow Jones Industrial Average fell 1.30% to close at 40,813.57, the S&amp;P 500 slid 1.39% to 5,521.52, and the Nasdaq Composite declined 1.96% to 17,303.01.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 rose 0.95% to 37,429.00, led by gains in the Power, Rubber and Chemical, Petroleum &amp; Plastic sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was up 0.83% and closed at 7,854.10, led by gains in the Metals &amp; Mining, Resources and Materials sectors.</li>
<li>India&#8217;s Nifty 50 rose 0.53% to 22,515.05, and Nifty 500 WAS UP 0.56% at 20,288.40.</li>
<li>China&#8217;s Shanghai Composite gained 0.19% to 3,426.13, and the Shanghai Shenzhen CSI 300 fell 0.24% to 3,996.79.</li>
<li>Hong Kong&#8217;s Hang Seng increased 0.77%, ending the session at 24,145.57.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was up 0.13%.</li>
<li>Germany&#8217;s DAX gained 0.28%.</li>
<li>France&#8217;s CAC rose 0.21%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.21%</li>
<li>European stocks edged higher Monday as hopes rose for a landmark German debt deal to boost economic growth.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.91% at $67.52/bbl, and Brent was up 0.89% at $71.21/bbl.</li>
<li>Oil prices rose Monday as U.S. strikes on Yemen&#8217;s Houthis and strong Chinese economic data boosted demand outlook despite no supply disruptions and lingering concerns over global growth and geopolitical tensions.     </li>
<li>Natural Gas gained 1.51% to $4.166.</li>
<li>Gold was trading higher by 0.10% at $3,004.46, Silver was down 0.32% to $34.323, and Copper rose 0.17% to $4.9048.</li>
<li>Gold edged higher Monday, trading near record highs as investors remained cautious ahead of the U.S. Fed meeting.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.47%, S&amp;P 500 futures fell 0.45% and Nasdaq 100 futures declined 0.44%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index slid 0.13% to 103.59, USD/JPY was down 0.01% to 148.61, and USD/AUD declined 0.40% to 1.5751.</li>
<li>The U.S. dollar neared a five-month low Monday, weighed by Trump&#8217;s trade policies and weak data, while the euro and yen gained on strong domestic drivers.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Rise, Gold Holds Above $3,000 - Global Markets Today While US Slept

Jefferies analyst Michael Yee initiates coverage on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy rating and announces Price Target of $135.

BPMC

Jefferies Initiates Coverage On Blueprint Medicines with Buy Rating, Announces Price Target of $135

Needham analyst Ryan Koontz reiterates Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and maintains $280 price target.

Reiteration

Needham Reiterates Buy on Fabrinet, Maintains $280 Price Target

BAER

Bridger Aerospace Board Appoints Sam Davis President And CEO, Effective March 17, 2025

Needham analyst Scott Berg reiterates Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $52 price target.

FIVN

Needham Reiterates Buy on Five9, Maintains $52 Price Target

BLCO

Bausch + Lomb Reveals US Launch Of Arise Lens Fitting System

Morgan Stanley analyst James Faucette maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Equal-Weight and lowers the price target from $380 to $372.

Morgan Stanley Maintains Equal-Weight on Accenture, Lowers Price Target to $372

This includes a non-cash expense of $34.3 M from an unrealized loss on derivative contracts, based on forward gold prices and contracted hedge price. The Company also incurred $4.1 M in exploration expenditures, primarily related to the Johnson Tract drilling program.

CTGO

Contango FY24 EPS $(3.49) Vs $(5.61) YoY

DA Davidson analyst Lucky Schreiner upgrades Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from Neutral to Buy and maintains the price target from $350 to $350.

Upgrades

MNDY

DA Davidson Upgrades Monday.Com to Buy, Maintains Price Target to $350

Needham analyst Scott Berg reiterates BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and maintains $100 price target.

BILL

Needham Reiterates Buy on BILL Holdings, Maintains $100 Price Target

Needham analyst Scott Berg reiterates Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and maintains $25 price target.

FRSH

Needham Reiterates Buy on Freshworks, Maintains $25 Price Target

Needham analyst Tom Nikic maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy and lowers the price target from $84 to $80.

Needham Maintains Buy on Nike, Lowers Price Target to $80

Press Releases

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Health Care

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

General

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Comments

BioCardia

BioCardia (BCDA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL